Organisation paid for research Program year 2024 Source: CMS Open Payments

Columbus Regional Research Instit LLC

Neither a doctor nor a teaching hospital

Research payments

$65,404

37 payments

Through program year 2024, Columbus Regional Research Instit LLC is reported as receiving $65,404 in research payments, across 37 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $4,360 2
2023 Research $20,500 3
2022 Research $2,070 5
2021 Research $12,188 18
2020 Research $23,534 6
2019 Research $2,752 3

Breakdown

Who paid Research payments · program years 2019–2024
  1. Sanofi US Services Inc. $50,949 33 payments
  2. Sanofi-Aventis U.S. LLC $13,500 1 payment
  3. Genzyme Corporation $955 3 payments
Studies the money was for Research payments · program years 2019–2024
  1. Single Arm, Open-label Study to Assess the Safety and Pharmacokinetics of a 14-day Regimen of Teplizumab in Pediatric Stage 2 Type 1 Diabetes (Participants With at Least Two Autoantibodies and Dysglycemia) $13,500 1 payment
  2. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $10,700 1 payment
  3. Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) $9,880 23 payments
  4. A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable $7,250 2 payments
  5. A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naive People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial $7,000 2 payments
  6. Phase 2 Window Study of Two Dose Levels of SAR439859 (SERD) Versus Letrozole in Newly Diagnosed Pre-operative Post-menopausal Patients With ER Positive, HER2 Negative Primary Breast Cancer (AMEERA-4) $4,750 1 payment
  7. A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent-Onset Type 1 Diabetes Mellitus $3,988 1 payment
  8. Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine $2,428 1 payment
  9. A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapie $1,626 1 payment
  10. A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Di $1,625 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record